Search Results - "Recknor, Chris"

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis by Cosman, Felicia, Eriksen, Erik Fink, Recknor, Chris, Miller, Paul D, Guañabens, Núria, Kasperk, Christian, Papanastasiou, Philemon, Readie, Aimee, Rao, Hanumantha, Gasser, Jürg A, Bucci‐Rechtweg, Christina, Boonen, Steven

“…Clinical data suggest concomitant therapy with bisphosphonates and parathyroid hormone (PTH) may blunt the anabolic effect of PTH; rodent models suggest that…”
Get full text

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture by Lyles, Kenneth W, Colón-Emeric, Cathleen S, Magaziner, Jay S, Adachi, Jonathan D, Pieper, Carl F, Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A, Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K, Abrams, Ken, Orloff, John J, Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven

“…Mortality is increased in the year after a hip fracture, and strategies that improve the outcome are needed. This randomized, double-blind, placebo-controlled…”
Get full text

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study by EISMAN, John A, CIVITELLI, Roberto, MAIRON, Nicole, MASANAUSKAITE, Daiva, REID, David M, DELMAS, Pierre D, RECKER, Robert R, ADAMI, Silvano, CZERWINSKI, Edward, RECKNOR, Chris, PRINCE, Richard, REGINSTER, Jean-Yves, ZAIDI, Mone, FELSENBERG, Dieter, HUGHES, Claire

“…OBJECTIVE: An effective and well tolerated intravenous (IV) bisphosphonate could provide a new treatment method for patients with osteoporosis. The Dosing…”
Get full text

Hospitalization in High Fracture Risk Older Adults with Osteoporosis Using the Safe Functional Motion Test: A Longitudinal Analysis by Van Dussen, Daniel J., Recknor, Chris P., Recknor, Julie C.

“…The Safe Functional Motion Test (SFM-5) is a five item performance based clinical assessment tool quantifying habitual daily movement that may increase the…”
Get full text

Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture by Eriksen, Erik Fink, Lyles, Kenneth W, Colón‐Emeric, Cathleen S, Pieper, Carl F, Magaziner, Jay S, Adachi, Jonathan D, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Lavecchia, Catherine, Hu, Huilin, Boonen, Steven, Mesenbrink, Peter

“…Annual infusions of zoledronic acid (5 mg) significantly reduced the risk of vertebral, hip, and nonvertebral fractures in a study of postmenopausal women with…”
Get full text

Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial by Hofbauer, Lorenz C, Witvrouw, Richard, Varga, Zsuzsanna, Shiota, Naofumi, Cremer, Malika, Tanko, Laszlo B, Rooks, Daniel, Auberson, Lixin Zhang, Arkuszewski, Michal, Fretault, Nathalie, Schubert-Tennigkeit, Agnes Annette, Papanicolaou, Dimitris A, Recknor, Chris

“…Older adult patients (ie, those aged ≥60 years) undergoing surgery for hip fracture repair frequently experience loss of muscle mass and strength due to poor…”
Get full text

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study by Adachi, Jonathan D, Bone, Henry G, Daizadeh, Nadia S, Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A, Wang, Andrea, Lin, Celia J F, Wagman, Rachel B, Ferrari, Serge

“…Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who…”
Get full text

Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis by DEVOGELAER, Jean-Pierre, ADLER, Robert A, RECKNOR, Chris, SEE, Kyoungah, WARNER, Margaret R, WONG, Mayme, KROHN, Kelly

“…Objective. This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 μ…”
Get full text

Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial by Brown, Jacques P., Chines, Arkadi, Chapurlat, Roland, Foldes, Joseph, Nogues, Xavier, Civitelli, Roberto, De Villiers, Tobias, Massari, Fabio, Zerbini, Cristiano, Yang, Wenjing, Recknor, Chris, Libanati, Cesar

Get full text

Scores on the safe functional motion test are associated with prevalent fractures and fall history by Recknor, Chris P, Grant, Stephanie L, Recknor, Julie C, Macintyre, Norma J

“…The Safe Functional Motion test (SFM) was developed to measure observed body mechanics and functional motion associated with spine load, balance, strength, and…”
Get full text

Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass by Genant, Harry K, Engelke, Klaus, Bolognese, Michael A, Mautalen, Carlos, Brown, Jacques P, Recknor, Chris, Goemaere, Stefan, Fuerst, Thomas, Yang, Yu‐Ching, Grauer, Andreas, Libanati, Cesar

“…ABSTRACT Romosozumab, a monoclonal antibody that binds sclerostin, has a dual effect on bone by increasing bone formation and reducing bone resorption, and…”
Get full text

Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: a randomized study by Lewiecki, E Michael, Czerwinski, Edward, Recknor, Chris, Strzelecka, Anna, Valenzuela, Guillermo, Lawrence, Mary, Silverman, Stuart, Cardona, Jose, Nattrass, Susan M, Binkley, Neil, Annett, Miriam, Pearman, Leny, Mitlak, Bruce

“…Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC). The objective of this study was to evaluate…”
Get full text

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis by Dempster, David W, Zhou, Hua, Rao, Sudhaker D, Recknor, Chris, Miller, Paul D, Leder, Benjamin Z, Annett, Miriam, Ominsky, Michael S, Mitlak, Bruce H

“…Anabolic osteoporosis drugs improve bone mineral density by increasing bone formation. The objective of this study was to evaluate the early effects of…”
Get full text

The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial by Czerwinski, Edward, Cardona, Jose, Plebanski, Rafal, Recknor, Chris, Vokes, Tamara, Saag, Kenneth G, Binkley, Neil, Lewiecki, E Michael, Adachi, Jonathan, Knychas, Dorota, Kendler, David, Orwoll, Eric, Chen, Yinzhong, Pearman, Leny, Li, Y Heather, Mitlak, Bruce

“…ABSTRACT Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral,…”
Get full text

Zoledronic acid for prevention and treatment of osteoporosis by Recknor, Chris

“…Osteoporosis (OP) is associated with a high risk of fracture and disability and with substantial medical costs. This paper is a review of the intravenous…”
Get more information

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy: A Randomized Open-Label Trial by Recknor, Chris, Czerwinski, Edward, Bone, Henry G., Bonnick, Sydney L., Binkley, Neil, Palacios, Santiago, Moffett, Alfred, Siddhanti, Suresh, Ferreira, Irene, Ghelani, Prayashi, Wagman, Rachel B., Hall, Jesse W., Bolognese, Michael A., Benhamou, Claude-Laurent

“…To compare the efficacy and safety of denosumab to ibandronate in postmenopausal women with low bone mineral density (BMD) previously treated with a…”
Get full text

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density by Poole, Kenneth ES, Treece, Graham M, Pearson, Rose A, Gee, Andrew H, Bolognese, Michael A, Brown, Jacques P, Goemaere, Stefan, Grauer, Andreas, Hanley, David A, Mautalen, Carlos, Recknor, Chris, Yang, Yu‐Ching, Rojeski, Maria, Libanati, Cesar, Whitmarsh, Tristan

“…ABSTRACT Romosozumab monoclonal antibody treatment works by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone…”
Get full text

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial by McClung, Michael, Miller, Paul, Recknor, Chris, Mesenbrink, Peter, Bucci-Rechtweg, Christina, Benhamou, Claude-Laurent

“…To evaluate the efficacy of zoledronic acid in the prevention of bone loss in postmenopausal women with low bone mass. In this 2-year, randomized, multicenter,…”
Get full text

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab by Keaveny, Tony M, McClung, Michael R, Genant, Harry K, Zanchetta, Jose R, Kendler, David, Brown, Jacques P, Goemaere, Stefan, Recknor, Chris, Brandi, Maria L, Eastell, Richard, Kopperdahl, David L, Engelke, Klaus, Fuerst, Thomas, Radcliffe, Hoi‐Shen, Libanati, Cesar

“…ABSTRACT In the randomized, placebo‐controlled FREEDOM study of women aged 60 to 90 years with postmenopausal osteoporosis, treatment with denosumab once every…”
Get full text

Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial by Rooks, Daniel, Swan, Therese, Goswami, Budhaditya, Filosa, Lee Anne, Bunte, Ola, Panchaud, Nicolas, Coleman, Laura A, Miller, Ram R, Garcia Garayoa, Elisa, Praestgaard, Jens, Perry, Robert G, Recknor, Chris, Fogarty, Charles M, Arai, Hidenori, Chen, Liang-Kung, Hashimoto, Jun, Chung, Yoon-Sok, Vissing, John, Laurent, Didier, Petricoul, Olivier, Hemsley, Sarah, Lach-Trifilieff, Estelle, Papanicolaou, Dimitris A, Roubenoff, Ronenn

“…The potential benefit of novel skeletal muscle anabolic agents to improve physical function in people with sarcopenia and other muscle wasting diseases is…”
Get full text